开源证券:给予诺诚健华买入评级

证券之星
18 May

开源证券股份有限公司余汝意,汪晋,余克清近期对诺诚健华进行研究并发布了研究报告《公司信息更新报告:核心单品销售强劲增长,持续加速国际化进程》,给予诺诚健华买入评级。诺诚健华(688428)核心单品奥布替尼销售强劲增长,上调全年销售指引至35%2024年,公司实现营收10.09亿元,同比增长36.68%;归母净利润-4.40亿元,扣非归母净利润-4.40亿元。单看2025Q1,公司实现营收3.81...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10